Femasys Inc
FEMY0.861USD
+0.064+7.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
40.73MMarket Cap
LossP/E TTM
More Details of Femasys Inc Company
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Femasys Inc Info
Ticker SymbolFEMY
Company nameFemasys Inc
IPO dateJun 18, 2021
CEOLee-Sepsick (Kathy)
Number of employees69
Security typeOrdinary Share
Fiscal year-endJun 18
Address3950 Johns Creek Court
CitySUWANEE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code30024
Phone17705003910
Websitehttps://www.femasys.com/
Ticker SymbolFEMY
IPO dateJun 18, 2021
CEOLee-Sepsick (Kathy)
Company Executives of Femasys Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Independent Director
Independent Director
--
--
Mr. Daniel Currie
Mr. Daniel Currie
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ms. Christine Thomas
Ms. Christine Thomas
Chief Regulatory and Clinical Officer
Chief Regulatory and Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
432.85K
+12.63%
Mr. Alistair Milnes
Mr. Alistair Milnes
Independent Director
Independent Director
5.67K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
80.00
--
Mr. Dov Elefant
Mr. Dov Elefant
Chief Financial Officer
Chief Financial Officer
--
--
Dr. James Liu, M.D.
Dr. James Liu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
409.27K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chernett (Jorey)
5.19%
Dauntless Investment Group, LLC
2.96%
Uzialko (Edward R Jr.)
2.08%
The Vanguard Group, Inc.
1.63%
Alumni Capital Management LLC
1.59%
Other
86.55%
Shareholders
Shareholders
Proportion
Chernett (Jorey)
5.19%
Dauntless Investment Group, LLC
2.96%
Uzialko (Edward R Jr.)
2.08%
The Vanguard Group, Inc.
1.63%
Alumni Capital Management LLC
1.59%
Other
86.55%
Shareholder Types
Shareholders
Proportion
Individual Investor
8.41%
Investment Advisor
5.54%
Investment Advisor/Hedge Fund
2.29%
Venture Capital
0.08%
Research Firm
0.04%
Bank and Trust
0.03%
Hedge Fund
0.03%
Other
83.57%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
53
6.06M
9.41%
--
2025Q3
60
6.06M
10.92%
+931.90K
2025Q2
65
5.13M
15.23%
+1.22M
2025Q1
62
3.90M
17.97%
-962.46K
2024Q4
57
2.39M
11.54%
+713.58K
2024Q3
55
1.67M
11.99%
+32.62K
2024Q2
57
1.64M
11.51%
+117.87K
2024Q1
57
1.52M
11.83%
-1.09M
2023Q4
56
1.43M
10.18%
-232.64K
2023Q3
51
1.66M
10.47%
+405.22K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chernett (Jorey)
3.03M
7.05%
+1.41M
+86.81%
Jun 30, 2025
Dauntless Investment Group, LLC
2.32M
5.4%
+745.63K
+47.34%
Jun 30, 2025
Uzialko (Edward R Jr.)
1.22M
2.83%
--
--
Apr 08, 2025
The Vanguard Group, Inc.
951.87K
2.21%
+126.20K
+15.28%
Jun 30, 2025
Alumni Capital Management LLC
931.90K
2.17%
+931.90K
--
Sep 04, 2025
Lee-Sepsick (Kathy)
432.85K
1.01%
+48.53K
+12.63%
Aug 27, 2025
Geode Capital Management, L.L.C.
251.39K
0.58%
+5.89K
+2.40%
Jun 30, 2025
Clear Creek Financial Management, LLC
281.82K
0.66%
+11.45K
+4.23%
Jun 30, 2025
Currie (Daniel Scott)
109.24K
0.25%
+19.61K
+21.88%
Jun 02, 2025
BlackRock Institutional Trust Company, N.A.
92.41K
0.21%
+56.73K
+159.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Femasys Inc?
The top five shareholders of Femasys Inc are:
Chernett (Jorey) holds 3.03M shares, accounting for 7.05% of the total shares.
Dauntless Investment Group, LLC holds 2.32M shares, accounting for 5.40% of the total shares.
Uzialko (Edward R Jr.) holds 1.22M shares, accounting for 2.83% of the total shares.
The Vanguard Group, Inc. holds 951.87K shares, accounting for 2.21% of the total shares.
Alumni Capital Management LLC holds 931.90K shares, accounting for 2.17% of the total shares.
Chernett (Jorey) holds 3.03M shares, accounting for 7.05% of the total shares.
Dauntless Investment Group, LLC holds 2.32M shares, accounting for 5.40% of the total shares.
Uzialko (Edward R Jr.) holds 1.22M shares, accounting for 2.83% of the total shares.
The Vanguard Group, Inc. holds 951.87K shares, accounting for 2.21% of the total shares.
Alumni Capital Management LLC holds 931.90K shares, accounting for 2.17% of the total shares.
What are the top three shareholder types of Femasys Inc?
The top three shareholder types of Femasys Inc are:
Chernett (Jorey)
Dauntless Investment Group, LLC
Uzialko (Edward R Jr.)
Chernett (Jorey)
Dauntless Investment Group, LLC
Uzialko (Edward R Jr.)
How many institutions hold shares of Femasys Inc (FEMY)?
As of 2025Q4, 53 institutions hold shares of Femasys Inc, with a combined market value of approximately 6.06M, accounting for 9.41% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.52%.
What is the biggest source of revenue for Femasys Inc?
In FY2025Q2, the -- business generated the highest revenue for Femasys Inc, amounting to -- and accounting for --% of total revenue.
